Home > Healthcare > Pharmaceuticals > Finished Drug Form > Female Sexual Dysfunction Treatment Market

Female Sexual Dysfunction Treatment Market Trends

Report ID: GMI9138
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Female Sexual Dysfunction Treatment Market Trends

The landscape of female sexual dysfunction (FSD) treatment is undergoing a transformative shift propelled by a surge in research and development (R&D) activities aimed at addressing this prevalent yet often overlooked condition. As awareness grows and societal taboos surrounding sexual health diminish, researchers, healthcare professionals, and pharmaceutical companies are increasingly dedicating resources to unravelling the complexities of FSD and developing innovative treatment modalities.

Increased R&D efforts lead to a deeper understanding of the underlying causes and mechanisms of FSD. This understanding is crucial for developing more effective treatment strategies.
R&D activities foster innovation leading to the development of novel treatment options for FSD. This can include new medications, devices, and therapeutic approaches tailored specifically to address the various subtypes of FSD.
Similarly, advancements in R&D enable personalized treatment approaches tailored to individual factors such as genetics, hormones, and psychology enhancing efficacy and patient satisfaction. Increased research awareness reduces societal stigma around FSD, encouraging more individuals to seek treatment without fear of judgment. Thus, escalating the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Female sexual dysfunction treatment market size was USD 495.3 million in 2023 and is expected to register 10% CAGR from 2024-2032 owing to the increasing advancements in medical technology in the field of female sexual dysfunction (FSD) treatment worldwide.

The estrogen therapy segment is expected to reach USD 797.2 million by 2032 due to its capability to help alleviate vaginal dryness, itching, and discomfort which are common symptoms of FSD.

The U.S. female sexual dysfunction treatment industry is expected to register 9.7% CAGR from 2024-2032 due to well-developed healthcare infrastructure with modern facilities, advanced medical technology, and highly trained healthcare professionals in the region.

Cipla Limited, Freya Pharma Solutions, GSK plc, Lawley Pharmaceuticals Pty Ltd., Merck & Co., Inc., Millicent Pharma Limited, Novo Nordisk, Pfizer, Inc., and Sprout Pharmaceuticals, Inc., are some of the major female sexual dysfunction treatment companies worldwide.